Remission versus response as the goal of therapy in ADHD: a new standard for the field?

Abstract:

BACKGROUND:Attention-deficit/hyperactivity disorder (ADHD) has a substantial negative impact; however, within long-term follow-up studies, a proportion of patients do very well, both symptomatically and functionally, suggesting that the lower the symptom burden, the greater the functional improvements. Studies in major depressive disorder have identified a relationship between symptomatic remission and restoration of normal functioning. OBJECTIVE:The purpose of this article was to propose a definition of remission in ADHD, review remission rates in clinical trials for commonly used medications, and explore the relationship between symptomatic remission and optimal functioning. METHODS:Remission and response rates for medications were obtained through MEDLINE searches of English-language citations (1999-2005) and meeting abstracts (2003-2005) using the terms amphetamine, atomoxetine, methylphenidate, ADHD, efficacy, effectiveness, and controlled trial, as well as hand searches of efficacy studies. Evidence from randomized controlled trials, as well as effectiveness studies, where the proportions of patients achieving predefined cutoff points for remission or response are reported, was reviewed. Because higher remission rates were identified with the oral, osmotic, controlled-release system (OROS) of methylphenidate, a relationship between symptomatic response/remission and optimal functioning was explored further. RESULTS:Remission in ADHD should be defined as a loss of diagnostic status, minimal or no symptoms, and optimal functioning when individuals are being treated with or without medication. Symptomatic remission can be operationalized as a mean total score of S1 on most standardized questionnaires. For the medications examined (OROS methylphenidate, immediate-release methylphenidate, atomoxetine, and mixed amphetamine salts), response rates were comparable at approximately 70% to 75%; however, remission rates were higher with OROS methylphenidate compared with either immediate-release methylphenidate or atomoxetine (remission rates with amphetamines were not found). Benefits, including decreased illness burden as well as improved psychosocial and academic functioning, were associated with treatment versus no treatment and were greater with medication that offered higher remission rates. CONCLUSIONS:The literature provided evidence that greater symptom improvements are associated with greater functional improvements, emphasizing that remission of ADHD as defined should be the goal of therapy. Treatment ought to include the early use of strategies with the greatest chance of achieving remission. Future clinical research should use remission as the primary outcome.

journal_name

Clin Ther

journal_title

Clinical therapeutics

authors

Steele M,Jensen PS,Quinn DM

doi

10.1016/j.clinthera.2006.11.006

subject

Has Abstract

pub_date

2006-11-01 00:00:00

pages

1892-908

issue

11

eissn

0149-2918

issn

1879-114X

pii

S0149-2918(06)00276-1

journal_volume

28

pub_type

杂志文章,评审
  • Role of Intestinal Microbiome in Lipid and Glucose Metabolism in Diabetes Mellitus.

    abstract:PURPOSE:The contribution of intestinal bacterial strains (gut microbiota) in human metabolism and obesity is being increasingly recognized. The goal of this article was to provide a commentary on the clinical usefulness of these data. METHODS:We performed a review of the currently available articles on PubMed. FINDIN...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2015.03.008

    authors: van Olden C,Groen AK,Nieuwdorp M

    更新日期:2015-06-01 00:00:00

  • In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at Forty US Hospitals.

    abstract:BACKGROUND:Treatment of infections caused by gram-negative bacilli is increasingly challenging because of emerging resistance. Current surveillance data are informative, but may not discern differences by infection site and clinical setting, and do not incorporate pharmacodynamic (PD) characteristics when determining s...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clinthera.2009.11.021

    authors: Eagye KJ,Kuti JL,Sutherland CA,Christensen H,Nicolau DP

    更新日期:2009-11-01 00:00:00

  • Pharmacokinetic profile of cisapride 20 mg after once- and twice-daily dosing.

    abstract::Cisapride is a substituted piperidinyl benzamide. It is chemically related to metoclopramide but lacks the antidopaminergic properties of metoclopramide that affect the central nervous system and cause extrapyramidal side effects. Cisapride is indicated for the symptomatic treatment of patients with nocturnal heartbur...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1016/s0149-2918(98)80092-1

    authors: Zhou H,Herron J,Clyde C,Lee P,Mechlinski W,Pesco-Koplowitz L

    更新日期:1998-03-01 00:00:00

  • Evaluation of dronedarone use in the US patient population between 2009 and 2010: a descriptive study using a claims database.

    abstract:BACKGROUND:The utilization pattern of dronedarone was unknown, especially regarding prescribers' compliance with the product's prescribing information (PI) following its availability and the implementation of the Food and Drug Administration-approved risk evaluation and mitigation strategy for the drug in the United St...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2011.08.013

    authors: Gao S,Juhaeri J,Schiappacasse HA,Koren AT,Dai WS

    更新日期:2011-10-01 00:00:00

  • Flumazenil and seizures: analysis of 43 cases.

    abstract::Flumazenil is a new drug indicated for the reversal of the sedative effects of benzodiazepines mediated at the benzodiazepine-receptor site. Worldwide sources to date have disclosed 43 cases of seizures related, at least temporally, to the intravenous administration of flumazenil. There was no apparent relationship be...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:

    authors: Spivey WH

    更新日期:1992-03-01 00:00:00

  • Management of worsening multiple sclerosis with mitoxantrone: a review.

    abstract:BACKGROUND:Mitoxantrone, an intravenously administered immunosuppressant that inhibits T-cell, B-cell, and macrophage proliferation, is indicated for reducing neurologic disability and relapse frequency in patients with secondary progressive multiple sclerosis (SPMS), progressive relapsing MS, or worsening relapsing-re...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2006.04.013

    authors: Fox EJ

    更新日期:2006-04-01 00:00:00

  • Effect of Gabapentin Enacarbil on Individual Items of the International Restless Legs Study Group Rating Scale and Post-sleep Questionnaire in Adults with Moderate-to-Severe Primary Restless Legs Syndrome: Pooled Analysis of 3 Randomized Trials.

    abstract:PURPOSE:Few studies have investigated restless legs syndrome (RLS) treatment effects on individual International RLS Study Group Rating Scale (IRLS) items. We assessed the effects of gabapentin enacarbil (GEn) on individual IRLS items and their correlation with sleep disturbances in adults with moderate-to-severe prima...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.clinthera.2016.05.008

    authors: Ahmed M,Hays R,Steven Poceta J,Jaros MJ,Kim R,Shang G

    更新日期:2016-07-01 00:00:00

  • Regulation of biotechnology products in the global pharmaceutical market: the case of the European community and the United States.

    abstract::Biotechnology represents an opportunity for innovative products, new markets, or capital investments, depending on one's perspective. A primary consideration in regulating this industry is to ensure that innovation is not stifled yet the public is protected from potentially unsafe or ineffective products. We compared ...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:

    authors: Hakim Z,Kucukarslan S

    更新日期:1993-03-01 00:00:00

  • Treating hypertension to reduce cardiovascular risk: a Korean perspective.

    abstract:BACKGROUND:Hypertension usually clusters with other cardiovascular risk factors; however, it has not been reported whether hypertension treatment has an impact on the awareness and treatment of other cardiovascular risk factors such as diabetes mellitus and hypercholesterolemia. OBJECTIVE:To analyze the effect of hype...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2012.05.006

    authors: Kim KI,Kim CH

    更新日期:2012-07-01 00:00:00

  • Fluoxetine tenth anniversary update: the progress continues.

    abstract::This tenth anniversary review/update of fluoxetine concentrates on the past 5 years of its clinical application. The mechanism of action of fluoxetine; its metabolism; its efficacy in patients with various diagnostic subgroups of depression, patients with coincident medical disease, children and adolescents with depre...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0149-2918(97)80066-5

    authors: Stokes PE,Holtz A

    更新日期:1997-09-01 00:00:00

  • Synergistic aerobic and anaerobic infections.

    abstract::Encapsulation affects the virulence and survival of anaerobic bacteria and their protection from phagocytosis. More encapsulated Bacteroides strains and anaerobic and facultative gram-positive cocci are isolated from patients with clinical infections than from healthy people. The pathogenicity of Bacteroides, Fusobact...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:

    authors: Brook I

    更新日期:1987-01-01 00:00:00

  • Pharmacokinetics and tolerability of extended-release clarithromycin.

    abstract:BACKGROUND:Clarithromycin is a semisynthetic macrolide that exhibits broad-spectrum activity against gram-positive, gram-negative, and atypical respiratory tract and skin/skin structure pathogens, Mycobacterium species, and Helicobacter pylori. It is indicated for the treatment of a wide variety of respiratory and derm...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/s0149-2918(01)80060-6

    authors: Guay DR,Gustavson LE,Devcich KJ,Zhang J,Cao G,Olson CA

    更新日期:2001-04-01 00:00:00

  • The effects of enalapril on blood pressure, renal hemodynamics, and renal function.

    abstract::Since the introduction of angiotensin converting enzyme (ACE) inhibitors into clinical use, much information has been accumulated in animal models and man regarding their effects on renal function in different disease states. Enalapril, the first nonsulfhydryl ACE inhibitor approved for general use in the United State...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:

    authors: Weir MR

    更新日期:1989-09-01 00:00:00

  • Real-time Assessment of the Development and Function of the Placenta Across Gestation to Support Therapeutics in Pregnancy.

    abstract::The placenta is vital to the health and development of the fetus, serving to deliver oxygen and nutrients, facilitate the removal of waste products, and provide a barrier to pathogens and other harmful substances present in the maternal circulation. When these processes fail to operate normally, they can lead to compl...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2020.11.002

    authors: Weinberg DH

    更新日期:2020-11-24 00:00:00

  • Potential health care cost savings associated with early treatment of multiple sclerosis using disease-modifying therapy.

    abstract:BACKGROUND:Clinical trials have shown that treatment with disease-modifying therapies (DMTs), such as interferon, at the time of clinically isolated syndrome can delay the onset of multiple sclerosis (MS). OBJECTIVES:The objective of this study was to assess health care utilization and expenditures associated with tre...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2011.05.049

    authors: Curkendall SM,Wang C,Johnson BH,Cao Z,Preblick R,Torres AM,Knappertz V,Gondek K

    更新日期:2011-07-01 00:00:00

  • Adherence to premixed insulin in a prefilled pen compared with a vial/syringe in people with diabetes in Singapore.

    abstract:BACKGROUND:The real-world clinical effectiveness of exogenous insulin is limited by nonadherence. Various insulin delivery systems have been developed to help improve adherence, with prefilled pens gaining popularity among adult Singaporeans with diabetes. However, adherence to insulin in people with diabetes in Singap...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2014.05.009

    authors: Cheen HH,Lim SH,Huang MC,Bee YM,Wee HL

    更新日期:2014-07-01 00:00:00

  • Does type of bolus insulin matter in the hospital? Retrospective cohort analysis of outcomes between patients receiving analogue versus human insulin.

    abstract:BACKGROUND:Poor glycemic control in hospitalized patients has been associated with increased morbidity and mortality. Research suggests that analogue bolus insulin may be more effective in achieving blood glucose (BG) control compared with human bolus insulin. OBJECTIVE:This study compares mortality, length of stay (L...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2010.10.009

    authors: Ko KJ,Tomor V,Nathanson BH,Bouchard JR,Aagren M,Dubois RW

    更新日期:2010-10-01 00:00:00

  • Conscientious objection and abortifacient drugs.

    abstract::The legal right to assert a conscientious objection is reviewed, using as an example the dispensing of abortifacient drugs by pharmacists. The three areas of law that most significantly concern the right to assert a conscientious refusal are employment law, conscience clauses, and religious discrimination law. Each of...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Brushwood DB

    更新日期:1993-01-01 00:00:00

  • Randomized trials of dopamine agonists in restless legs syndrome: a systematic review, quality assessment, and meta-analysis.

    abstract:BACKGROUND:The use of dopamine agonists (DAs) for the treatment of restless legs syndrome (RLS) has been assessed in numerous randomized clinical trials (RCTs). OBJECTIVES:The aims of this study were to assess the reporting quality of published RCTs according to the Consolidated Standards of Reporting Trials (CONSORT)...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.clinthera.2010.01.028

    authors: Zintzaras E,Kitsios GD,Papathanasiou AA,Konitsiotis S,Miligkos M,Rodopoulou P,Hadjigeorgiou GM

    更新日期:2010-02-01 00:00:00

  • Safety and Efficacy of Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Myocardial Infarction in the Presence of Intracoronary Thrombus: An Analysis From the Grand Drug-eluting Stent Registry.

    abstract:PURPOSE:To evaluate the safety and efficacy of glycoprotein IIb/IIIa inhibitors (GPIs) in patients with acute myocardial infarction (AMI) in the presence of intracoronary thrombus undergoing percutaneous coronary interventions. METHODS:This study, performed from January 1, 2004, to November 31, 2014, at 55 centers in ...

    journal_title:Clinical therapeutics

    pub_type: 信件,多中心研究

    doi:10.1016/j.clinthera.2020.02.022

    authors: Zheng C,Kang J,Yang HM,Han JK,Park KW,Kang HJ,Koo BK,Kim HS

    更新日期:2020-05-01 00:00:00

  • Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg.

    abstract:BACKGROUND:The effectiveness of a drug is significantly influenced by a patient's adherence to the required regimen. OBJECTIVE:The goal of this retrospective database analysis was to determine the factors affecting adherence over a 12-month follow-up period in adults with type 2 diabetes mellitus (DM) initiating once-...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2013.03.021

    authors: Malmenäs M,Bouchard JR,Langer J

    更新日期:2013-06-01 00:00:00

  • Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.

    abstract:BACKGROUND:Hypersensitivity reactions consist of a variable group of clinical findings and have been described for a wide variety of chemical compounds. OBJECTIVE:This review characterizes the clinical profile of hypersensitivity to the nucleoside reverse transcriptase inhibitor abacavir sulfate. METHODS:We performed...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/s0149-2918(01)80132-6

    authors: Hetherington S,McGuirk S,Powell G,Cutrell A,Naderer O,Spreen B,Lafon S,Pearce G,Steel H

    更新日期:2001-10-01 00:00:00

  • Leuprorelin acetate depot vs danazol in the treatment of endometriosis: results of an open multicentre trial.

    abstract::A national multicentre trial was organized in order to compare the efficacy and safety of leuprorelin acetate depot and danazol in the treatment of endometriosis. Sixty-seven patients with pelvic endometriosis of different severity at laparoscopy were included in the study and followed during the 24 weeks of treatment...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Crosignani PG,Gastaldi A,Lombardi PL,Montemagno U,Vignali M,Serra GB,Stella C

    更新日期:1992-01-01 00:00:00

  • A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia.

    abstract:PURPOSE:The objective of this study was to evaluate the efficacy and tolerability of a triple combination of amlodipine/losartan/rosuvastatin in patients with hypertension and hypercholesterolemia. METHODS:A randomized, multicenter, double-blind, placebo-controlled study was conducted. Eligible patients with hypertens...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clinthera.2017.10.013

    authors: Lee HY,Kim SY,Choi KJ,Yoo BS,Cha DH,Jung HO,Ryu DR,Choi JH,Lee KJ,Park TH,Oh JH,Kim SM,Choi JY,Kim KH,Shim J,Kim WS,Choi SW,Park DG,Song PS,Hong TJ,Rhee MY,Rha SW,Park SW

    更新日期:2017-12-01 00:00:00

  • Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers.

    abstract:BACKGROUND:Empagliflozin is a sodium glucose cotransporter 2 inhibitor in clinical development as a treatment for type 2 diabetes mellitus. OBJECTIVE:The goal of this study was to investigate potential drug-drug interactions between empagliflozin and verapamil, ramipril, and digoxin in healthy volunteers. METHODS:The...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clinthera.2013.02.015

    authors: Macha S,Sennewald R,Rose P,Schoene K,Pinnetti S,Woerle HJ,Broedl UC

    更新日期:2013-03-01 00:00:00

  • Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers.

    abstract:BACKGROUND:Avanafil is a selective phosphodiesterase type 5 inhibitor being developed for the treatment of erectile dysfunction. OBJECTIVE:This study was conducted to meet Korean regulatory requirements for the marketing of avanafil. To this end, tolerability and pharmacokinetic properties of single and multiple oral ...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clinthera.2010.06.011

    authors: Jung J,Choi S,Cho SH,Ghim JL,Hwang A,Kim U,Kim BS,Koguchi A,Miyoshi S,Okabe H,Bae KS,Lim HS

    更新日期:2010-06-01 00:00:00

  • Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials.

    abstract:BACKGROUND:Metastatic bone disease is a serious clinical problem in patients with advanced cancer. Bisphosphonates inhibit the activity of osteoclasts and are the treatment of choice for bone metastases. OBJECTIVE:This article reviews the efficacy and safety data from Phase III trials of ibandronate in metastatic bone...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2004.12.010

    authors: Tripathy D,Body JJ,Bergström B

    更新日期:2004-12-01 00:00:00

  • Review of the therapeutic uses of liraglutide.

    abstract:BACKGROUND:Glucagon-like peptide (GLP-1) is a neuroendocrine hormone that increases blood glucose and is a drug target for treatment of type 2 diabetes. Liraglutide, a subcutaneous, once-daily GLP-1 agonist, is approved for the treatment of type 2 diabetes in the United States and Europe. It also has been studied for w...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2011.06.004

    authors: Ryan GJ,Foster KT,Jobe LJ

    更新日期:2011-07-01 00:00:00

  • Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children.

    abstract:BACKGROUND:Gastroesophageal reflux disease (GERD), which is reflux that produces damage or troubling symptoms, afflicts approximately 7% of infants and children to the extent that administration of physician-directed pharmacotherapy is warranted. OBJECTIVE:This study was designed in conjunction with the US Food and Dr...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clinthera.2005.04.008

    authors: Orenstein SR,Gremse DA,Pantaleon CD,Kling DF,Rotenberg KS

    更新日期:2005-04-01 00:00:00

  • Acute interstitial nephritis associated with moxifloxacin use.

    abstract:BACKGROUND:Moxifloxacin is a fluoroquinolone antimicrobial agent with proven efficacy against community-acquired respiratory pathogens. Common adverse effects associated with its use include gastro-intestinal symptoms, but nephrotoxicity has not yet been reported to the manufacturer or in the literature (based on a MED...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2005.08.008

    authors: Argirov M,Ricken G,Zecher D,Fischereder M

    更新日期:2005-08-01 00:00:00